Exploiting molecular targets in pancreatic cancer

Hematology/Oncology Clinics of North America

Volumn 16, Issue 1, 2002, Pages 139-157

  Wolff, Robert A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CETUXIMAB; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FK 506 BINDING PROTEIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; ONCOPROTEIN; ONYX 015; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RAPAMYCIN DERIVATIVE; REBIMASTAT; SEMAXANIB; TANOMASTAT; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL CYCLE PROTEINS; CLINICAL TRIALS, PHASE III; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RESEARCH DESIGN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036262402     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(01)00012-0     Document Type: Review

References (117)

1. Phase II study of anti-epidermal growth factor receptor cetuximab (IM-C225) in patients with advanced pancreatic cancer
2. Blocking oncogenic Ras signaling for cancer therapy
3. A phase I trial of the famesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
4. A phase I trial of the famesyl transferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer
5. Most human carcinomas of the exocrine pancreas contain mutant c-K-Ras genes
6. A role of the kinase mTOR in cellular transformation induced by the oncoprotcins P3k and Akt
7. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
8. Phase I trial of weekly paclitaxel and BMS412662 in patients with advanced solid tumors
9. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
10. ZD1839 (lressa) as an anticancer agent
11. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
12. A phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
13. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
14. The matrix metalloproteinases and their inhibitors in pancreatic cancer from molecular science to a clinical application
15. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
16. Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
17. Epidermal growth factor receptor blockade with (225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
18. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (Herceptin)
19. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
20. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
21. Dose escalation study of oral famesyl transfeRase inhibitor BMS-214662 in patients with solid tumors
22. Increasing complexity of Ras signaling
23. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
24. K-Ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster
25. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (lressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
26. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (lressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
27. Herceptin: From the bench to the clinic
28. Analysis of p53. p21WAFl, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival
29. Recombinant human angiostatin: A phase I clinical trial assessing safety, pharmacokinetics, and pharmacodynamics
30. Prevalence and clinical significance of combined K-Ras mutation and p53 aberration in pancreatic adenocarcinoma
31. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
32. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition
33. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia
34. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma
35. Phase I and pharmacokinetic study of the oral famesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
36. Famesyl transferase inhibitors: Current developments and future perspectives
37. Cancer of the pancreas
38. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
39. Therapeutic application of anti-growth factor receptor antibodies
40. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-Ras ribozyme
41. Seed and soil revisited: Contribution of the organ microenvironment to cancer metastasis
42. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor
43. Tumor angiogenesis: A possible control point in tumor growth
44. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
45. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
46. BAY 12 9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
47. Pharmaceutical research in molecular oncology
48. Famesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
49. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
50. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells
51. Pharmacokinetic evaluation of BMS-275291, a matrix metalloproteinase inhibitor, in cancer patients
52. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site
53. Feasibility of multiple direct injections of Onyx-015 adenovirus into pancreatic carcinomas under endoscopic ultrasound guidance
54. Overexpression of HER-2 in ovarian carcinomas
55. Phase I clinical trial of recombinant human endostatin in patients with solid tumors: Pharmacokinetic, safety, and efficacy analysis using surrogate endpoints of tissue and radiographic response
56. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
57. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
58. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods
59. Activation of the MAP kinase pathway by the protein kinase raf
60. A phase I trial of BMS-275291: A novel non-hydrozamate, sheddase-sparing matrix metalloproteinase inhibitor with no dose-limiting arthritis
61. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene
62. The association of K-Ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma
63. Tumor angiogenesis: Past, present and the near future
64. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
65. Phase I study of famesyl transferase inhibitor BMS-214662 in solid tumors
66. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemo-sensitivity and decreased expression of multiple chemoresistance genes
67. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma
68. Treatment of metastatic pancreatic adenocarcinoma: A comprehensive review
69. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix
70. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
71. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas
72. What is the true rate of K-Ras mutation in carcinoma of the pancreas?
73. p53 status and the efficacy of cancer therapy in vivo
74. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry
75. Interactions between adenovirus proteins and the p53 pathway: The development of ONYX-015
76. Epidermal growth factor receptor inhibition by a monoclonal antibody as anti-cancer therapy
77. The EGF receptor family as targets for cancer therapy
78. Application of CT in the investigation of angiogenesis in oncology
79. Specific inhibition of K-Ras expression and tumorigenicity of lung cancer cells by antisense RNA
80. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-O15) into primary carcinomas of the pancreas: A phase I trial
81. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
82. The preclinical evaluation of angiogenesis inhibitors
83. Angiostatin induces and sustains dormancy of human primary tumors in mice
84. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
85. Updated results of a prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF n high-risk primary breast cancer involving ten or more axillary lymph nodes: CALGB9082/SWOG9114NCIC-Ma13
86. A phase I clinical and pharmacokinetic trial of the famesyl transferase inhibitor R115777 + docetaxel: A promising combination in patients with solid tumors
87. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
88. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
89. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
90. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma
91. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
92. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12 9566 on a protracted oral daily dosing schedule in patients with solid malignancies
93. Ras protein famesyltransferase: A strategic target for anticancer therapeutic development
94. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
95. Cetuximab (IM-C225) plus irinotecan(CPT-11) is active in CPT-11 refractory colorectal cancer that expresses epidermal growth factor receptor
96. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test
97. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma
98. Randomized, double blind, placebo controlled trial of marimastat in patients with small cell lung cancer following response to first-line chemotherapy: An NCIC-CTG and EORTC study
99. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
100. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
101. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
102. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis
103. K-Ras-independent effects of the famesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity. G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells
104. Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials
105. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
106. Marimastat (BB2516): Current status of development
107. Marimastat: The clinical development of a matrix metalloproteinase inhibitor
108. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
109. Expression of c-erbB-2 oncoprotein in human thyroid tumours
110. Cnrrent clinical trials administering the antiangiogenesis agent SU5416
111. Genentech H0650 study investigators: First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: A preliminary report
112. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
113. Novel therapies for pancreatic cancer
114. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
115. Effect of angiostatin on liver metastasis of pancreatic cancer in hamsters
116. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
117. Phase I and pharmacokinetic study of famesyl protein transferase inhibitor R115777 in advanced cancer